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Abstract
Background: Energy deficiency and mitochondrial failure have been recognized as a prominent, early event in Alzheimer’s
disease (AD). Recently, we demonstrated that chronic exposure to amyloid-beta (Ab) in human neuroblastoma cells over-
expressing human wild-type amyloid precursor protein (APP) resulted in (i) activity changes of complexes III and IV of the
oxidative phosphorylation system (OXPHOS) and in (ii) a drop of ATP levels which may finally instigate loss of synapses and
neuronal cell death in AD. Therefore, the aim of the present study was to investigate whether standardized Ginkgo biloba
extract LI 1370 (GBE) is able to rescue Ab-induced defects in energy metabolism.
Methodology/Principal Findings: We used a high-resolution respiratory protocol to evaluate OXPHOS respiratory capacity
under physiological condition in control (stably transfected with the empty vector) and APP cells after treatment with GBE.
In addition, oxygen consumption of isolated mitochondria, activities of mitochondrial respiratory enzymes, ATP and reactive
oxygen species (ROS) levels as well as mitochondrial membrane mass and mitochondrial DNA content were determined. We
observed a general antioxidant effect of GBE leading to an increase of the coupling state of mitochondria as well as energy
homeostasis and a reduction of ROS levels in control cells and in APP cells. GBE effect on OXPHOS was even preserved in
mitochondria after isolation from treated cells. Moreover, these functional data were paralleled by an up-regulation of
mitochondrial DNA. Improvement of the OXPHOS efficiency was stronger in APP cells than in control cells. In APP cells, the
GBE-induced amelioration of oxygen consumption most likely arose from the modulation and respective normalization of
the Ab-induced disturbance in the activity of mitochondrial complexes III and IV restoring impaired ATP levels possibly
through decreasing Ab and oxidative stress level.
Conclusions/Significance: Although the underlying molecular mechanisms of the mode of action of GBE remain to be
determined, our study clearly highlights the beneficial effect of GBE on the cellular OXPHOS performance and restoration of
Ab-induced mitochondrial dysfunction.
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Introduction
Standardized Ginkgo biloba extract (GBE) derived from dried
leaves of Ginkgo tree is a valuable therapeutic drug for the
treatment of memory impairment and dementia including Alzhei-
mer’s disease (AD). A number of clinical studies repeatedly showed
the improvement of cognitive symptoms in the elderly and in AD
patients [1–5] but negative data have also been published. The
discussion about the benefits of GBE for different indications has
beenrevitalized after the publication of two major trials: (i) the study
by McCarney and colleagues [6] demonstrating no evidence of
effectivenessofGBEinmildtomoderatedementiaand(ii)theGEM
study by DeKosky and colleagues [7] showing no favourable effect
ofGBEforthe preventionofdementiaonsetinolderpeoplewithout
or with only mild cognitive impairment. GBE exhibits a complex
mode of action. Notably, multiple effects on mitochondrial function
and on the apoptotic pathway that seems to be crucial for its
beneficial effects in AD were reported: stabilization of mitochon-
drial membrane potential, improvement of energy metabolism, up-
regulation of anti-apoptotic Bcl-2 protein and down-regulation of
pro-apoptotic Bax protein, inhibition of cytochrome c release,
reduction of caspase 9 and caspase 3 activity after oxidative stress
and reduction of apoptotic cell death [8–14]. However, evidence
how GBE influences the mitochondrial oxidative phosphorylation
system (OXPHOS) in neuronal cells is lacking.
AD is characterized by amyloid-beta (Ab)-containing plaques,
neurofibrillary tangles, as well as synapse and neuron loss. Ab
which represents with tau the main neuropathological hallmarks of
AD is supposed to play a pivotal role in the pathogenesis of the
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and energy metabolism deficiencies have been recognized as
earliest events [10,15] and have been correlated with impairments
of cognitive abilities in AD clinical scenario [16]. The most
consistent defect in mitochondrial electron transport system (ETS)
enzymes in AD is the deficiency in cytochrome c oxidase (complex
IV) activity in post-mortem brain tissues of AD patients [17–19]
and APP transgenic mice [20], as well as in other tissues, such as
platelets from AD patients and AD cybrid cells [21,22]. Moreover,
abnormal mitochondrial dynamics may play a role in mitochon-
drial dysfunction in AD [23,24]. Interestingly, few years ago, the
target of interest of Ab toxic species switched from its extracellular,
fibrillar form to its soluble, oligomeric form [23,25] emphasising
the important early role of mitochondria in AD pathogenic
pathways [10,24,26,27].
In line with these findings, we recently reported that chronic
exposure to Ab in human neuroblastoma cells (SH-SY5Y) over-
expressing human wild-type APP (APP cells) resulted in an
impairment of the respiratory capacity of OXPHOS and a drop in
ATP generation by complex V which in turn may initiate cell
death pathway [28].
Therefore, the aim of the present study was to investigate the
potential effect of standardized GBE LI 1370 on Ab-induced
mitochondrial dysfunction in APP cells. In addition to the
measurement of oxygen consumption in whole cells as well as of
isolated mitochondria, we examined activities of mitochondrial
enzymes assembling the ETS. Based on previous studies
[11,29,30] we decided to focus on the more important
mitochondrial respiratory enzymes implicated in AD and aging,
that are the complexes I, III and IV. Furthermore, we determined
ATP and reactive oxygen species (ROS) levels as well as the
mitochondrial membrane mass. Finally, we studied the mitochon-
drial DNA/nuclear DNA ratio using real-time PCR to determine
changes at the genetic level.
Results
GBE did not modify cells morphology but decreased
oxidative stress
As described in our previous study [28], transfection of SH-
SY5Y cells with cDNAs (pCEP4 vector) containing the vector
alone or the entire coding region of human APP (APP695) did not
significantly change the general morphological aspect of cells
(Fig. 1A). Similarly, vector control as well as APP cells conserved
their neuroblast-like morphology with differentiated perikaria and
short neurites after treatment with GBE (Fig. 1B). APP cells
showed a slight trend to increased ROS levels compared to
controls cells (Fig. 1C). Mitochondria-associated ROS levels
decreased significantly in both cell lines after treatment with
GBE (100 mg/ml) for 24 h (Fig. 1D).
GBE ameliorated OXPHOS capacity and restored Ab-
induced deficits
To investigate the protective effect of GBE against Ab toxicity at
the mitochondrial level, we used a high-resolution respiratory
protocol established lately by our group [28]. Thus, physiological
substrate combinations (pyruvate, glutamate and malate as
substrates for complex I and succinate for complex II) were used
to obtain mitochondrial bioenergetics approaching the most of
physiological states in whole cells (Fig. 2A). We compared
OXPHOS that is the whole ETS composed of the four
mitochondrial enzymes (complex I to complex IV) and the
F1F0ATP synthase of vital control and APP cells after pre-
treatment with GBE for 24 h. As already previously observed [28],
APP cells exhibited a significant impairment of OXPHOS
capacity (Fig. 2B). Of note, GBE was able to significantly
ameliorate the global failure of mitochondrial respiration in APP
cells and increased oxygen consumption in control cells as well
(Fig. 2B). Importantly, GBE-treated control and APP cells
presented comparable mitochondrial respiratory rate validating
the protective role of GBE on stabilization and normalization of
mitochondrial capacity, respectively (Fig. 2B).
To analyse the impact of GBE on metabolic states of
mitochondrial respiration, two flux control ratios have been
evaluated. First, the respiratory control ratio (RCR) which is an
indicator of the coupling state of mitochondria was determined.
State 3 is the rate of phosphorylating respiration in the presence of
exogenous ADP, when mitochondria are actively making ATP,
whereas state 4 is the rate of resting respiration, when all ADP has
been consumed. State 4 is associated with proton leakage across
the inner mitochondrial membrane, when mitochondria exhibit
basal activity, i.e. they are respiring but not making ATP.
Therefore, RCR represents the ADP-activated flux to measure
coupled OXPHOS capacity (state3) divided by leak flux (state4).
Whereas increased Ab levels led to a decrease of RCR in APP
cells, treatment with GBE significantly increased the ratio in both
cell types (Fig. 3A). Secondly, ROX/ETS yields an index of the
magnitude of residual oxygen consumption relative to maximum
oxygen consumption capacity. This ratio was decreased in both
cell types after treatment with GBE with the strongest effect in
APP cells (Fig. 3B). Both flux control ratio changes indicate an
increase of the coupling state of mitochondria leading to a better
efficiency of OXPHOS. Consistent with this result, we observed a
rise of ATP levels which are closely correlated with a higher
complex V activity, the final OXPHOS enzyme, in GBE-treated
control and APP cells (Fig. 3C).
Taken together, respiratory analyses showed that GBE
enhanced metabolic pathways by increasing the coupling state
of OXPHOS promoting finally a rise of ATP synthesis in both
cell types but with the strongest effects on APP cells. As a
consequence, GBE-treated control and APP cells presented
comparable mitochondrial respiratory system capacity suggesting
a complete restoration of Ab-induced deficits in energy
metabolism.
GBE improved oxygen consumption in isolated
mitochondria from APP cells and led to an up-regulation
of mitochondrial DNA
To confirm the improvement of mitochondrial performance
observed in whole cells, we investigated oxygen consumption of
mitochondria that were isolated from control and APP cells after
24 h treatment with GBE. Consistent with our results on whole
cells, isolated mitochondria from APP cells still exhibited a
significant impairment of OXPHOS capacity and reduced RCR
compared to mitochondria isolated from control cells (Fig. 4A and
B). Again, GBE-induced enhancement of oxygen consumption
was significantly present in both cell lines (Fig. 4A) with the
strongest improvement in APP cells (Fig. 4A and B) suggesting a
regulatory effect of GBE at the mitochondrial level even after its
removal. Of note, this functional enhancement can be associated
with an increase of the mitochondrial DNA/nuclear DNA ratio
after treatment with GBE (Fig. 4C) but without a change of the
mitochondrial membrane mass (Fig. 4D).
GBE modulated the activity of respiratory complexes
To improve the mitochondrial respiratory capacity, GBE may
act on one or several mitochondrial enzymes. To study this
GBE Ameliorates OXPHOS
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investigated. Complex I activity significantly increased after GBE
treatment selectively in APP cells (Fig. 5A), whereas complex II
activity was unaffected by GBE in both cell lines (data not shown).
Complex III activity which was markedly increased in APP cells
was normalized to the level of control cells after treatment with
GBE (Fig. 5B). Complex IV activity which was decreased in APP
cells, significantly increased in control and APP cells after
treatment with GBE (Fig. 5C).
GBE partially decreased Ab secretion of APP cells
To delineate the relationship between Ab level and GBE, we
further examined the levels of secreted Ab1-40 in control and APP
cells. Figure 6 shows that APP cells secreted Ab to a 3–4 fold
higher extent than control cells bearing the empty vector. Of note,
treatment with GBE significantly decreased medium Ab levels in
APP cells of about 20% (medium Ab1-40, APP cells:
100%64.8%, APP cells + GBE: 83.22%62.6%, control cells:
22.03 60.4%, control cells + GBE: 21.06%60.5%).
Discussion
In this study, we present for the first time clear evidence that
under physiological conditions GBE improved metabolic energy
pathways by increasing the coupling state of mitochondria.
Importantly, the comparison of the mitochondrial energetic
capacity in both cell types after treatment with GBE indicates a
recovery of the disturbed bioenergetic homeostasis found in APP
cells. Notably, GBE-enhancing effect on OXPHOS was still
present in mitochondria after their removal from cells suggesting
possible continuing, regulatory actions of GBE at the mitochon-
drial level. These results corroborate findings showing an increase
of the coupling state of isolated mitochondria by GBE in ischemia
models [31] and findings demonstrating that GBE ameliorated
oxygen consumption of mitochondria from rat heart mainly driven
by effects of GBE on complex I and III [29]. The capacity of
mitochondria to re-phosphorylate ADP in state 3 is positively
dependent on the degree of coupling. In accordance with this
assumption, we also observed an enhancement of ATP levels in
Figure 1. GBE did not modify cell morphology but decreased reactive oxygen species (ROS) levels. Morphological analysis of vector
control and APP cells showed neuroblast-like morphology with differentiated perikaria (arrows) and occasional short neurites (arrowheads).
A) Transfection of SH-SY5Y cells with cDNAs (pCEP4 vector) containing the vector alone or the entire coding region of wild-type human APP (APP
cells) and B) GBE treatment (100 mg/ml; 24 h) did not significantly change general cell morphology. Scale bars: 50 mm. At least 200 cells were
analyzed for each cell line and condition. C) Mitochondria-associated ROS levels measured after incubation with DHR (DHR fluorescence units/1610
5
cells). ROS levels showed a trend to be increased in APP cells compared to control cells (
(*
)p=0.082, unpaired student’s t-test, n=11, values represent
the means 6 S.E.). D) ROS levels (DHR fluorescence units/1610
5 cells normalized to the respective untreated control and APP cells=100%) were
significantly decreased after treatment with GBE (100 mg/ml; 24 h). Values represent the means 6 S.E., number of pairs n=5, paired student’s t-test:
##,p ,0.01; ###,p ,0.001 GBE treated versus corresponding untreated cells.
doi:10.1371/journal.pone.0012359.g001
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in whole cells. O2 flux and O2 consumption by vital cells were measured after addition of different agents: pyruvate/glutamate (pyr/glu), digitonin
(dig), ADP, glutamate (glu), succinate (suc), cytochrome c (cyt c), FCCP, rotenone (rot), antimycine A (AA). B) Two-way ANOVA revealed a significant Ab-
induced decrease of the total cellular respiration in APP cells compared to that of control cells (group effect: control vs. APP p,0.001). Two-way
ANOVA revealed also a significant effect of GBE (100 mg/ml; 24 h) on total O2 consumption. Indeed, respiratory rates of mitochondria were increased
in GBE-treated control and APP cells corresponding to that of their respective cell type (Two-way ANOVA, effect of GBE treatment in control cells
p,0.001 and APP cells p,0.001). Values represent the means 6 S.E. from n=5 assays (measurements of control and APP cells were performed in
parallel). Post-hoc analysis for single experimental respiratory conditions: GBE treatment effect, paired student’s t-test, number of pairs n=5: #,
p,0.05, ##,p ,0.01; ###,p ,0.001 GBE treated versus corresponding untreated cells; and effect of Ab, unpaired student’s t-test, n=5, **, p,0.01;
***, p,0.001 APP versus control cells). Values represent means 6 S.E.
doi:10.1371/journal.pone.0012359.g002
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respiration rate in state 3 is determined by the activity of
mitochondrial enzymes of the whole ETS and ATP-synthase
[29,30]. Thus, the global improvement of mitochondria function-
ality may be explained by the action of GBE on one or several
mitochondrial enzymes. The increased activity of complex III in
APP cells that can be interpreted as a compensatory mechanism to
rescue Ab-induced mitochondrial defects [29] normalized after
treatment with GBE. This effect can be taken as a back to a
physiological functionality, i.e. the over-activity of complex III in
untreated APP cells was down-regulated in the presence of GBE
which in turn up-regulated complex IV activity and ATP
synthesis, both markedly reduced in our AD cell model.
Surprisingly, complex I activity was increased only in APP cells
after treatment with GBE while it was unchanged in control cells.
APP cells did not exhibit an Ab-induced defect in complex I
activity compared to control cells [29]. GBE by increasing the
coupling mitochondrial state may improve complex I activity.
Complex I as a main ROS producer may also be a key element in
GBE efficacy. However, this can not explain why the GBE effect
on complex I was only found in APP cells. One can speculate that
a damaged ETS with changes in downstream complexes, such as
complex III and IV in APP cells, might force the emergence of this
effect. Our study is further in line with recent findings studying the
effect of GBE after in vivo treatment on mitochondrial membrane
potential in dissociated brain cells from aged mice after inhibiting
OXPHOS using specific inhibitors of complexes [11]. Here, GBE
showed protective effects on mitochondrial membrane potential at
the complexes I, IV and V [11]. Even if the exact molecular
mechanisms by which GBE stabilizes mitochondrial enzymes is
not yet clear, it can be speculated that besides other regulatory
effects on mitochondrial components: (i) GBE may act as an
antioxidant scavenging superoxide anion generated by electron
leakage which occurs mainly at complexes I and III. (ii) GBE may
also scavenge nitric oxide leading to an increase of complex IV
activity which is the main target of NO [32]. Consequently, the
protection of mitochondrial complexes by GBE may not only lead
to an increase of mitochondrial performance (coupling state) but
also to a decrease of ROS production. Moreover, some authors
proposed that GBE provides anti-apoptotic effects [8,9,33]. Thus,
GBE significantly attenuated mitochondria-initiated apoptosis and
decreased the activity of caspase 3, a key enzyme in the apoptosis
cell signalling cascade, in neuroblastoma cells stably expressing an
AD-associated double mutation in APP [12]. In addition, GBE
inhibited formation of Ab-fibrils [12] either by a direct interaction
with Ab [34,35] or by modulation of its precursor APP [36] and
GBE flavonols were able to reduce Ab levels in vitro and in the
brain from transgenic Alzheimer mice [37]. We also observed that
GBE treatment partially decreased Ab generation in APP cells.
Therefore, it might be possible that GBE restored impaired
OXPHOS pathway through decreasing Ab level, since Ab
interacts with mitochondria [27,29,31,38,39] and Ab levels
determine the extent of mitochondrial dysfunction [38]. Consid-
erable evidence exists that Ab can increase the production of ROS
[40]. Consistent, we found a slight increase in ROS levels in APP
cells compared to control cells suggesting that cellular antioxidant
defences are still able to counterbalance excessive ROS production
at least in part in our cell culture model.
Of note, we observed an up-regulation of mitochondrial DNA
in cells treated with GBE, suggesting that GBE may act not only at
a functional level of mitochondria but also at their genetic one.
The number of mitochondrial DNA copies per mitochondrion as
well as mitochondria per cell is exquisitely calibrated on cellular
energy demand. Mitochondrial DNA (mtDNA) encodes important
subunits of catalytic cores of mitochondrial respiratory complexes
constituting OXPHOS. Consequently, in our study the increase
Figure 3. GBE modulated mitochondrial flux control ratios and rose ATP synthesis. A) Respiratory control ratio (RCR) represents the
mitochondrial coupling state. RCR was decreased in APP cells and increased in GBE-treated control and APP cells. B) ROX/ETS yields an index of the
magnitude of residual oxygen consumption relative to the maximum oxygen consumption capacity. This ratio was decreased in GBE-treated control
and APP cells. C) ATP levels were decreased in APP cells and increased in GBE-treated control and APP cells. (A–C) Values represent the means 6 S.E.,
GBE treatment effect, paired student’s t-test, number of pairs n=5: #,p ,0.05, ##,p ,0.01 GBE treated versus corresponding untreated cells; and
effect of Ab, unpaired student’s t-test, n=5, *, p,0.05; ***, p,0.001 APP versus control cells.
doi:10.1371/journal.pone.0012359.g003
GBE Ameliorates OXPHOS
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(coupling state) may facilitate the assembly of mitochondrial
complexes into supercomplexes to optimize the respiratory
activity. This idea is in agreement with the results of D’Aurelio
and coworkers who revealed a correlation of improved mitochon-
drial respiration with the presence of supercomplexes [41].
Additionally, Tendi and colleagues [33] showed that GBE up-
regulated mitochondrial gene expression of a mtDNA encoded
subunit of complex I (ND1) in PC12 cells which may perfectly
correspond to the increase of complex I activity detected in our
GBE-treated APP cells. Moreover, the transcript level of the anti-
apoptotic Bcl-2-like protein was found to be elevated, whereas the
transcript level of the pro-apoptotic caspase 12 was decreased in
PC12 cells after treatment with GBE [9,12]. Although further
studies are necessary, we can speculate that a GBE treatment may
not only enhance mtDNA as an early event after acute treatment,
but may instigate mitochondria biogenesis as a long-term effect
after chronic exposure [42]. In line with this idea, recent studies
showed that GBE induced hippocampal neurogenesis, a very
energy demanding process, in young and old transgenic AD
mouse model (TgAPP/PS1) after receiving a diet supplemented
with GBE for 1 month [43].
Oxidative stress and especially mitochondria-derived oxidative
stress is thought to have an important role in the pathogenesis of
AD, a disease that likely begins years, if not decades, before clinical
onset of dementia. In line with this hypothesis, experimental data
support the notion that antioxidants may prevent or cure
pathological conditions of AD. With regard to beneficial effects
of antioxidants on OXPHOS performance, only few data are
available for other antioxidants than GBE. Thus, one study
provided evidence that vitamin E which is considered the major
lipophilic antioxidant in the human body has GBE-like beneficial
effects at high doses (corresponding to a human daily intake of
1,300 mg vitamin E/day) on age-dependent decline of OXPHOS
and enzyme activities I as well as IV in aging male mice brain [44].
But concerns have been raised about the long-term safety of
Figure 4. GBE enhanced oxygen consumption of isolated mitochondria and led to an up-regulation of mitochondrial DNA. A) Two-
way ANOVA revealed a significant Ab-induced decrease of the total cellular respiration in isolated mitochondria from APP cells compared to that of
control cells (group effect: control vs. APP p,0.001). Two-way ANOVA revealed also a significant effect of GBE (100 mg/ml; 24 h) on total O2
consumption of isolated mitochondria. Respiratory rates of mitochondria were increased in mitochondria from GBE-treated control and APP cells
corresponding to that of their respective untreated cell type (Two-way ANOVA, effect of GBE treatment in control cells p,0.001 and APP cells
p,0.001). Values represent the means 6 S.E. from n=3 assays (measurements of control and APP cells were performed in parallel). Post-hoc analysis
for single experimental respiratory conditions: GBE treatment effect, paired student’s t-test, number of pairs n=3: #,p ,0.05, ##,p ,0.01;
###,p ,0.001 GBE treated versus corresponding untreated cells; and effect of Ab, unpaired student’s t-test, n=3, **, p,0.01; ***, p,0.001 APP
versus control cells). B) RCR of isolated mitochondria was decreased in APP cells (effect of Ab, unpaired student’s t-test, n=3, **, p,0.01, APP versus
control cells) and increased in GBE-treated APP cells (GBE treatment effect, paired student’s t-test, number of pairs n=3: ##,p ,0.01, GBE treated
versus untreated APP cells). C) RT-PCR analyses revealed an increase of the mitochondrial DNA/nuclear DNA ratio from GBE-treated control and APP
cells (100 mg/ml; 24 h) compared to their corresponding untreated cells (number of pairs n=5, #,p ,0.05). D) Using MitoTracker Green FM
(fluorescence units/1610
5 cells), no change in mitochondrial mass was observed. (A–D) Values represent means 6 S.E.
doi:10.1371/journal.pone.0012359.g004
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evidence is provided demonstrating similar effects of vitamin E on
OXPHOS at lower and rather physiologically relevant doses.
MitoQ10 (mitochondria-targeted coenzyme Q) has also antioxi-
dant properties but only when electron flow within the respiratory
chain or complex I proton pumping is already retarded [45],
while, in contrast, MitoQ10 action in the intact respiratory chain
led to increased ROS production [45]. This is also contrary to our
results of GBE on OXPHOS performance and ROS levels under
non-pathological conditions found in control cells. Several
meaningful differences distinguish the mode of action of GBE
from those other antioxidants. Due to different constituents in the
extract such as flavonols, bilobalide, and ginkgolides, GBE seems
to exhibit a unique spectrum of action probably via complemen-
tary effects of its constituents [11] on mitochondrial function
including (i) direct radical scavenging properties, (ii) direct
stabilization of mitochondria, (iii) indirect protection of mitochon-
dria, and (iiii) up-regulation of mtDNA, leading to improved
OXPHOS performance and energy homeostasis. Whereas a huge
body of evidence from preclinical research support the notion that
antioxidants protect against neurodegeneration, previous observa-
tional studies of antioxidants, including vitamin E and GBE, and
dementia risk have yielded inconsistent results based on short- or
long-term follow-up periods [7,46] raising the question of the
Figure 5. GBE modulated the activities of mitochondrial ETS enzymes. A) Complex I activity (CI/CS ratio) was increased in GBE-treated
(100 mg/ml; 24 h) APP cells. B) Complex III activity (CIII/CS ratio) was increased in APP cells and decreased in GBE-treated APP cells (100 mg/ml; 24 h).
C) Complex IV activity (CIV/CS ratio) was decreased in APP cells and increased in GBE-treated control and APP cells (100 mg/ml; 24 h). (A–C) Values
represent the means 6 S.E., GBE treatment effect, paired student’s t-test, number of pairs n=4–6: #,p ,0.05, ##,p ,0.01 GBE treated versus
corresponding untreated cells; and effect of Ab, unpaired student’s t-test, n=4–6, **, p,0.01; ***, p,0.001 APP versus control cells.
doi:10.1371/journal.pone.0012359.g005
Figure 6. GBE decreased secretion of Ab1-40 in APP cells. Stably transfected APP cells secreted significantly higher amounts of Ab1-40 into the
medium than control cells bearing the empty vector. Secreted Ab1-40 was significantly decreased in GBE-treated APP cells (100 mg/ml; 24 h). Values
represent the means 6 S.E., GBE treatment effect, paired student’s t-test, number of pairs n=9: ##,p ,0.01; GBE treated versus untreated APP cells,
and effect of APP overexpression, unpaired student’s t-test, n=11–13: ***, p,0.001 APP versus control cells.
doi:10.1371/journal.pone.0012359.g006
GBE Ameliorates OXPHOS
PLoS ONE | www.plosone.org 7 August 2010 | Volume 5 | Issue 8 | e12359‘‘window of opportunity’’ for successful prevention. Further studies
should continue to assess points at which treatment might be most
relevant to dementia risk [47].
In total, our findings and findings of others indicate substantial
mitochondria modulating properties of GBE. We could clearly
show that GBE improved OXPHOS performance and was able to
restore Ab-induced mitochondria failure. Hereby, the increase in
mitochondrial content might represent an important early event.
Taking into account the increasing interest in mitochondrial
stabilization as intervention strategy in AD [48], the regulating
mechanisms of GBE on mitochondria function suggested by this
study qualifies this drug as therapeutic candidate.
Materials and Methods
Cell culture and treatment with GBE
In the present study, human neuroblastoma SH-SY5Y cells stably
expressing vector alone (pCEP4, control cells) or the entire coding
region of human wild-type APP (APP695, APP cells) were used as
described previously [49]. APP cells secreted Ab levels within pg/mL
range (around 150 pg/mL and 35 pg/mg protein respectively Ab1-40
compared to approximately 50 pg/mL and 10 pg/mg protein
respectively Ab1-40 secreted by vector control cells) [28]. Stably
transfected cell clones were selected with hygromycin [49]. Cells were
grown at 37uC in DMEM medium supplemented with 10% calf
serum, 2 mM L-glutamine, and 0.3 mg/mL hygromycin. Cells were
pre-treated with standardized Ginkgo biloba extract LI 1370 (Vifor SA,
Switzerland) for 24 h before analyzing the cells. A dose response for
GBE was tested by treating the cells with different GBE concentrations
starting from 0.001 mg/ml up to 0.5 mg/ml in distinct assays. The
optimum concentration of GBE yielding maximum beneficial effects
(with regard to reduction of ROS levels, enhancement of RCR, and
increase in ATP levels) in APP cells was 100 mg/ml (see figures S1, S2,
and S3, respectively), but significant beneficial effects could be detected
at concentration as low as 10 mg/ml (see ATP results, figure S3) and
50 mg/ml (seeROS and ATP results, figures S1and S3). Asimilar dose
response was found for control cells (see figures S1, S2, and S3,
respectively). Based on these findings and in agreement with other in
vitro studies [11,50], a standard concentration of 100 mg/ml of GBE
was used in the following assays. In further pre-experiments, we
excluded effects of the vehicle.
Phase contrast microscopy and morphological analysis
For the morphological analysis, cells were seeded at a density of
4610
4 cells/mL on coverslips previously coated with 0.05 mg/mL
collagen. Phase contrast pictures were taken from living neuroblas-
tomacellsusingaZeissAxiolab microscopewitha 406/1,2WKorr
objective equipped with a digital camera Zeiss AxioCam MRc.
Preparation of isolated mitochondria for the
determination of the activities of the single complexes I-IV
Cells were incubated for 15 min in an ice-cold lysis buffer
(75 mM NaCl, 1 mM NaH2PO4, 8 mM Na2HPO4, 250 mM
sucrose, 1 mM Pefabloc, 0.05% digitonine, complete protease
inhibitor mixture tabletsH (Roche Diagnostics)). Then, cells were
homogenized with a glass homogenizer (10 strokes at 400 rpm and
5 strokes at 700 rpm), and the resulting homogenate was
centrifuged at 800 g for 10 min at 4uC to remove nuclei and
tissue particles. The supernatant 1 (S1) was saved and the pellet
resuspended in the lysis buffer. The homogenization step as well as
the low-speed centrifugation step was repeated. The supernatant 2
(S2) was saved and added to S1. Combined mitochondria-
enriched supernatants (S1+S2) were centrifuged at 20,000 g for
15 min at 4uC to obtain the mitochondrial fraction. The
mitochondrial pellet was resuspended in PBS and stored at 4uC
until use, followed by determination of protein content [51].
Complex I activity
A total of 240 mg of isolated mitochondria was solubilized in
n-dodecyl b-D-maltoside (20%). NADH-ubiquinone oxidoreduc-
tase activity was measured at 30uC in a buffer containing 2 mM
Na
+/MOPS, 50 mM NaCl, and 2 mM KCN, pH 7.2, using
100 mM n-decylubiquinone (DBQ) and 100 mM NADH as
substrates and 5 mM rotenone as inhibitor [20,28,52,53].
Oxidation rate of NADH were recorded with a Shimadzu
Multi-Spec-1501 diode array spectrophotometer (e340–400 nm
=6.1 mM
21.cm
21). Complex I activity was normalized to citrate
synthase activity to take into account variations in the amount of
mitochondrial and non-mitochondrial protein contamination
between the samples [28,54] and was given as CI/CS ratio.
Complex III activity
The oxidation of 50 mM decylubiquinol obtained by complex
III was determined using cytochrome c as an electron acceptor as
described previously [28,55]. Briefly, decylubiquinol was prepared
by dissolving decylubiquinone (10 mM) in ethanol acidified to
pH 2. The quinone was reduced with excess solid sodium
borohydride. Decylubiquinol was extracted into diethylether:
cyclohexane (2:1, v/v) and evaporated to dryness under nitrogen
gas, dissolved in ethanol acidified to pH 2. The assay was carried
out in a medium containing 35 mM KH2PO4, 5 mM MgCl2,
2 mM KCN (pH 7.2), supplemented with 2.5 mg/mL BSA,
15 mM cytochrome c, 0,6 mM n-dodecyl b-D-maltoside and
5 mg/mL rotenone. The reaction was started with 10 mgo f
mitochondrial protein and the enzyme activity was measured at
550 nm. The extinction coefficient used for cytochrome c was
18.5 mM
21.cm
21. Complex III activity was normalized to citrate
synthase activity to take into account variations in the amount of
mitochondrial and non-mitochondrial protein contamination
between the samples [28,54] and was given as CIII/CS ratio.
Complex IV activity
Cytochrome c oxidase activity was determined in intact isolated
mitochondria (100 mg) using the Cytochrome c Oxidase Assay Kit
(Sigma-Aldrich GmbH, Buchs, Switzerland). The colorimetric
assay was based on the observation that a decrease in absorbance
at 550 nm of ferrocytochrome c was caused by its oxidation to
ferricytochrome c by cytochrome c oxidase. The Cytochrome c
Oxidase Assay was performed as described previously [28,53,56].
Complex IV activity was normalized to citrate synthase activity to
take into account variations in the amount of mitochondrial and
non-mitochondrial protein contamination between the samples
[28,54] and was given as CIV/CS ratio.
Reactive oxygen species (ROS) levels
Cells were plated the day before at a density of 1610
5 cells/well
in a 48 well plate. The mitochondria-associated ROS levels were
determined using the fluorescent dye dihydrorhodamine (DHR) at
a concentration of 10 mM. The cells were loaded for 15 min with
the dye. After washing twice with HBSS, the fluorescence was
determined with the Victor2 reader multiplate (PerkinElmer Life
Sciences) at 485 nm (excitation)/535 nm (emission).
Oxygen consumption of vital cells
Mitochondrial oxygen consumption was measured at 37uC using
an Oroboros Oxygraph-2k system. In contrast to the respiratory
protocol measuring oxygen consumption of isolated mitochondria
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the determination of oxygen consumption in whole, vital cells under
the most physiological conditions. Five millions of cells were added
to 2 mL of a mitochondrial respiration medium containing 0.5 mM
EGTA, 3 mM MgCl2, 60 mM K-lactobionate, 20 mM taurine,
10 mM KH2P04, 20 mM HEPES, 110 mM sucrose, 1g/l BSA
(pH 7.1). To measure state 4 (= state 2) of complex I, 5 mM
pyruvate and 2 mM malate were added and cells were permeabi-
lised with 15 mg/mL digitonin. Afterwards, 2 mM ADP was added
to measure state 3, and in order to increase the respiratory capacity,
10 mM glutamate was added. To study the effect of convergent
complex I+II electron input on respiration, 10 mM of succinate was
added [50]. The integrity of mitochondrial membrane was checked
through the addition of 10 mM cytochrome c. After determining
coupled respiration, 0.4 mM FCCP (Carbonyl cyanide p-(trifluoro-
methoxy) phenyl-hydrazone) was added and respiration was
measured in the absence of a proton gradient. In order to inhibit
complex I and III activities 0.5 mM rotenone and 2.5 mM
antimycine A, respectively were added. Then, 2 mM ascorbate
and 0.5 mM TMPD were added to have access to complex IV
activity. Finally, 100 mM sodium azide was added to inhibit the
mitochondrial respiration. Control and APP cells untreated or
treated with GBE were measured in parallel pairs using the same
conditions (crossover design).
Oxygen consumption of isolated mitochondria
The respiratory protocol used for isolated mitochondria was the
same than this for whole cells except for the following points: (i)
isolated mitochondria (0.5 mg) were added to 2 mL of a
mitochondrial respiration medium containing 65 mM sucrose,
10 mM potassium phosphate, 10 mM Tris-HCl, 10 mM MgSO4,
and 2 mM EDTA (pH 7.0), (ii) digitonin was not added and (iii)
0.05 mM of FCCP was sufficient to obtain the maximal
mitochondrial respiration [53].
Determination of ATP levels
Cells were plated one day before at a density of 2.5610
4 cells/
well in a white 96 well plate. The assay kit is based on the
bioluminescent measurement of ATP (ViaLightTM HT, Cambrex
Bio Science, Lonza, Rockland, USA). The bioluminescent method
utilizes the enzyme luciferase, which catalyses the formation of
light from ATP and luciferin. The emitted light was linearly
related to ATP concentration and was measured using a
luminometer [48,53].
Estimation of mitochondrial membrane mass
Cells were plated the day before at a density of 1610
5 cells/well
in a 48 well plate. Mitochondrial membrane mass was measured
using the cell-permeable mitochondria-selective dye MitoTracker
Green FM (Molecular Probes, Invitrogen, Lucerne, Switzerland)
(400 nM, 15 min). This probe accumulates in active mitochondria
independently of mitochondrial membrane potential and then
reacts with accessible thiol groups of proteins and peptides [57].
Fluorescence was determined using a Fluoroskan Ascent FL
multiplate reader (Labsystems) at 490 nm (excitation) /516 nm
(emission).
Quantitative real-time PCR for determination of
mitochondrial DNA/nuclear DNA ratio
Samples consisted of confluent grown SH-SY5Y cells (APP or
vector, untreated or treated for 24 h with GBE 100 mg/ml). Total
DNA was extracted with the Qiagen FlexiGen Kit (Qiagen, Basel,
Switzerland) according to the manufacturer’s protocol. To
determine the mitochondrial DNA (mtDNA) content in relation
to nuclear DNA (nDNA) for each sample [58,59,60] a standard
curve was generated via extracted DNA from pooled SH-SY5Y
cell populations. For this purpose, mitochondrial and genomic
genes were amplified using the same primers that were used for the
real-time PCR (see below) and templates were purified with the
Qiagen QIAquick PCR Purification Kit (Qiagen, Basel, Switzer-
land). The absorption at 260 nm was measured to determine the
gene copy number and produce serial standard dilutions.
Primers for the RT Q-PCR analysis of mitochondrial DNA
(mtDNA)-tRNAleu [61] were mtF3212 (59CACCAAGAACAG
GGTTTGT39) and mtR3319 (59TGGCCATGGGTATGTT
GTTAA39) [62], those for nuclear DNA (nDNA), human
polymerase c accessory subunit gene (ASPOLG) were ASPG3F
59GAGCTGTTGACGGAAAGGAG39 and ASPG4R (59CAG
AAGAGAATCCCGGCTAAG39) [63]. For each DNA extract,
the nDNA and mtDNA gene respectively were quantified
separately in triplicates and/or duplicates by real-time quantitative
PCR in the presence of SYBR-green with the use of the Applied
Biosystems StepOne
TM cycler (Applied-Biosystems). PCR reac-
tions contained 1x Power SYBR Green Master Mix (ABI P/N
4367659, Rotkreuz, Switzerland), 1 mM of each primer and 1 ng
of DNA extract. The PCR amplification consisted of a single
denaturation-enzyme-activation step of 10 min at 95uC, followed
by 40cycles of 15 sec denaturation at 95uC and 60 sec of
annealing/extension at 60uC. Fluorescence was measured at the
end of each extension step. A standard curve of corresponding
mtDNA and nDNA template equivalents with defined copy
numbers were included in each run to quantify the content of
mtDNA and nDNA in each sample. Data thus obtained were
analyzed by using the cycle threshold (CT) of each amplification
reaction relating it to its respective standard curve. Results from
the quantitative PCR were expressed as the ratio of the mean
mitochondrial DNA to the mean nuclear DNA content.
Detection of Ab levels
Detection of Ab1-40 secretion was performed by using
sandwich enzyme-linked immunosorbent assay (Invitrogen, Basel,
Switzerland) according to the manufacturer’s protocol. Secreted
Ab1-40 levels within the medium (Ab1-40 pg/ml) were normal-
ized to mg protein/ml. Values of intracellular Ab1-40 as well as
medium and intracellular Ab1-42 levels were below detection limit
and are therefore not shown.
Statistical Analysis
Data were presented as mean 6 S.E.M. For statistical
comparisons, unpaired and paired Student’s t-test, respectively,
or Two-way ANOVA was used. P values less than 0.05 were
considered statistically significant.
Supporting Information
Figure S1 GBE decreased reactive oxygen species (ROS) levels
in a dose response manner. Mitochondria-associated ROS levels
measured after incubation with DHR (DHR fluorescence units/
1610
5 cells normalized to the respective untreated control and
APP cells). A) Control cells showed significantly decreased ROS
levels after treatment with GBE (0.001–0.5 mg/ml; 24 h)
significantly for concentrations between 0.05–0.5 mg/ml. B)
GBE-treated APP cells (0.001–0.5 mg/ml; 24 h) exhibited signif-
icantly reduced ROS levels for the same concentration range
0.05–0.5 mg/ml compared to control cells. Values represent the
means 6 S.E., GBE treatment effect, paired student9s t-test,
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versus corresponding untreated control and APP cells.
Found at: doi:10.1371/journal.pone.0012359.s001 (3.94 MB TIF)
Figure S2 GBE modulated mitochondrial flux control ratios in a
dose response manner. Respiratory control ratio (RCR) was lower
in APP cells than in control cells. After treatment with GBE
(0.001–0.5 mg/ml; 24 h), RCR increased in control as well as in
APP cells from 0.01 mg/ml up to 0.1 mg/ml GBE (maximum
response in GBE treated APP cells). Values represent the means of
3 experiments.
Found at: doi:10.1371/journal.pone.0012359.s002 (1.33 MB TIF)
Figure S3 GBE rose ATP synthesis in a dose response manner.
A) Control cells showed increased ATP levels after treatment with
GBE (0.001–0.5 mg/ml; 24 h) significantly for concentrations
of 0.01 and 0.1 mg/ml. B) GBE-treated APP cells (0.001–0.5
mg/ml; 24 h) exhibited significantly increased ATP levels for
concentrations ranged between 0.01–0.1 mg/ml. Values represent
the means 6 S.E., GBE treatment effect, paired student’s t-test,
number of pairs n= 6: #,p ,0.05, ##,p ,0.01; GBE treated
versus corresponding untreated control and APP cells.
Found at: doi:10.1371/journal.pone.0012359.s003 (0.74 MB TIF)
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